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Background-—Glutamate metabolism may play a role in the pathophysiology of cardiometabolic disorders. However, there is
limited evidence of an association between glutamate-related metabolites and, moreover, changes in these metabolites, and risk of
cardiovascular disease (CVD).
Methods and Results-—Plasma levels of glutamate and glutamine were measured at baseline and 1-year follow-up in a case-cohort
study including 980 participants (mean age 68 years; 46% male) from the PREvencion con DIeta MEDiterranea (PREDIMED)
randomized trial, which assessed a Mediterranean diet intervention in the primary prevention of CVD. During median 4.8 years of
follow-up, there were 229 incident CVD events (nonfatal stroke, nonfatal myocardial infarction, or CVD death). In fully adjusted
models, per 1-SD, baseline glutamate was associated with 43% (95% CI: 16% to 76%) and 81% (39% to 137%) increased risk of
composite CVD and stroke alone, respectively, and baseline glutamine-to-glutamate ratio with 25% (6% to 40%) and 44% (25%
to 58%) decreased risk of composite CVD and stroke alone, respectively. Associations appeared linear for stroke (both
Plinear trend≤0.005). Among participants with high baseline glutamate, the interventions lowered CVD risk by 37% compared to
the control diet; the intervention effects were not signiﬁcant when baseline glutamate was low (Pinteraction=0.02). No signiﬁcant
effect of the intervention on year-1 changes in metabolites was observed, and no effect of changes themselves on CVD risk was
apparent.
Conclusions-—Baseline glutamate was associated with increased CVD risk, particularly stroke, and glutamine-to-glutamate ratio
was associated with decreased risk. Participants with high glutamate levels may obtain greater beneﬁts from the Mediterranean
diet than those with low levels.
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C ardiovascular disease (CVD) is the leading cause ofmortality in the world.1 Although CVD is to a large
degree both predictable and preventable through identiﬁca-
tion and modiﬁcation of traditional risk factors, its metabolic
and etiologic pathways are not completely understood.
Metabolites of glutamate (Glu) metabolism are related to
cardiometabolic factors. Previous studies have suggested that
glutamine (Gln)—a conditionally essential amino acid synthe-
sized from Glu and ammonia by glutamine synthetase and
produced mainly by muscle tissue2—enhances cardiac
recovery in mice and human.3,4 In cross-sectional studies,
plasma Glu levels were associated with higher body mass
index (BMI), blood pressure, and insulin resistance, whereas
Gln levels or glutamine-to-glutamate ratio (Gln:Glu) was
inversely associated with these parameters.5-8 Higher circu-
lating Gln:Glu ratios have also reportedly been associated
with a reduced risk of type 2 diabetes mellitus.2 Gln
supplementation in humans and animals improves glucose
homeostasis.2,9-11 These studies suggest that Glu metabolites
may play an important role in the pathophysiological mech-
anisms of CVD. They also can represent early biomarkers of
CVD. However, evidence that relates these metabolites
directly to CVD risk is limited. Moreover, previous studies
measured Glu metabolites on only a single occasion and did
not assess the effect of a randomized intervention on these
metabolites.
Diet is 1 main source of circulating Gln and Glu; diet as well
is 1 of the key modiﬁable factors in CVD development and
prevention. Various clinical trials have assessed dietary
modiﬁcations in CVD prevention, and they have shown
improvements of cardiometabolic risk factors and reductions
in the rate of clinical events.12-14 However, the underlying
mechanisms, especially with respect to the involved meta-
bolic pathways, are not completely understood. Understand-
ing the evolution of cardiometabolic morbidity, especially the
pathophysiological mechanisms involving metabolic effects of
dietary exposures, may be important in addressing CVD
prevention. In this context, interest in the traditional Mediter-
ranean diet has recently grown because it may represent the
ideal model for cardiovascular health. A better appraisal of the
mechanisms involved in the observed prevention of CVD
events by a Mediterranean diet is needed.15
The present research evaluates the hypothesis that
circulating levels of products of Glu metabolism are related
to CVD risk in a prospective case-cohort study within the
PREDIMED (“PREvencion con DIeta MEDiterranea”) trial, a
well-characterized, large, randomized, controlled dietary inter-
vention trial for the primary prevention of CVD. Secondarily,
because the human metabolome responds to15 and may
interact with changes in diet, we tested the hypotheses that
Mediterranean diet interventions inﬂuence changes in prod-
ucts of Glu metabolism and that the effects of these
metabolites can be modiﬁed by the cardioprotective effects
of the Mediterranean diet interventions.
Methods
Study Population and Design
The PREDIMED trial was a parallel-group, multicenter, ran-
domized trial of dietary interventions with a Mediterranean
diet supplemented with either nuts or extra-virgin olive oil for
the primary prevention of CVD. The design and primary results
of the trial have been published in detail.14,16 In brief, eligible
participants were men and women (55-80 years old) free of
CVD at enrollment, who had either type 2 diabetes mellitus or
at least 3 of the following major CVD risk factors: smoking,
hypertension, elevated low-density lipoprotein cholesterol
levels, low high-density lipoprotein cholesterol levels, over-
weight or obesity, or a family history of premature coronary
heart disease. Beginning on October 1, 2003, participants
were randomly assigned, in a 1:1:1 ratio, to 1 of 3 dietary
intervention groups: a Mediterranean diet (MedDiet) supple-
mented with extra-virgin olive oil (MedDiet+EVOO), a Mediter-
ranean diet supplemented with mixed nuts (MedDiet+nuts), or
a control diet in which the participants were advised to reduce
all types of fat intake. The primary endpoint was composite
CVD, deﬁned as nonfatal stroke, nonfatal myocardial infarc-
tion, or death from cardiovascular causes. During a median
follow-up time of 4.8 years (study end on December 1, 2010),
288 incident CVD events occurred.
We designed a case-cohort study17 within the PREDIMED
trial. Consistent with the case-cohort design, we included a
random, nonstratiﬁed sample of ~10% of PREDIMED partic-
ipants at baseline (“subcohort members,” N=788, including
751 “noncases” and 37 “incident internal cases”) in addition
to all other incident CVD cases (“incident external cases” who
were not “subcohort members,” N=192), for whom blood
samples were available (see Figure S1). Given the random
sampling of the study design, results of case-cohort studies
are generalizable to the entire cohort without a need to
ascertain the whole trial population.18
Our protocol included the speciﬁc assessment of the
following hypotheses on a potential relationship with CVD for
the following metabolites: (1) branched-chain and aromatic
amino acids; (2) the glutamine-cycling pathway; (3) small-
and medium-chain acylcarnitines; (4) gut ﬂora metabolites
such as choline and betaine; (5) urea-cycle metabolites; and
(6) lipids. The associations with branched-chain amino acids
(BCAAs) and acylcarnitines have already been published.19,20
Here, we present the results for the second hypothesis,
which relates to the glutamine-cycling pathway. The trial
protocol was approved by the Institutional Review Boards at
participating institutions across Spain; the present study
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protocol was approved by the Institutional Review Boards at
all study locations involved (eg, at institutions across Spain
and at the Harvard T. H. Chan School of Public Health in
Boston, MA). All study participants provided written,
informed consent.
Measurement of Metabolites
Fasting blood samples were collected by PREDIMED nurses at
baseline and yearly thereafter during follow-up. After an
overnight fast, plasma EDTA tubes were collected, and
aliquots were coded and kept refrigerated until they were
stored at 80°C. Pairs of samples (baseline and ﬁrst-year
visit samples from each participant) were randomly ordered
and shipped on dry ice to the Broad Institute for metabo-
lomics analyses.
Amino acids, including Glu and Gln, were proﬁled using
liquid chromatography-tandem mass spectrometry (LC-MS) on
a system comprised of a Shimadzu Nexera X2 U-HPLC
(Shimadzu Corp, Marlborough, MA) coupled to a Q Exactive
hybrid quadrupole orbitrap mass spectrometer (Thermo Fisher
Scientiﬁc, Waltham, MA). Metabolite identities were con-
ﬁrmed using authentic reference standards. Raw data were
processed using TraceFinder software (Thermo Fisher Scien-
tiﬁc, Waltham, MA) and Progenesis QI (Nonlinear Dynamics,
Newcastle upon Tyne, UK). The detailed mass spectrometry
setting was previously described.20 The analytical coefﬁcients
of variation for glutamine and glutamate measurements were
both 0.04.
Case Ascertainment
The PREDIMED primary endpoint was the incidence of
composite CVD, consisting of nonfatal stroke, nonfatal
myocardial infarction, or cardiovascular death. Information
on primary endpoints was collected by study physicians who
were blinded to the intervention and from other sources of
information, such as the National Death Index. This
anonymized information was sent to the Clinical Endpoint
Committee, which adjudicated the events blinded to the
intervention groups. The primary outcome in the present
study was composite CVD as deﬁned above, and our
secondary outcome was limited to the incidence of nonfatal
stroke, because stroke was the most common CVD endpoint
(48%) in PREDIMED participants.
Covariate Assessment
Medical conditions and risk factors were collected using a
questionnaire during the ﬁrst screening visit. Weight, height,
other anthropometric measures, and blood pressure were
directly measured by the PREDIMED nurses. A general
medical questionnaire was administered on a yearly basis
regarding participant lifestyle factors such as smoking, family
history of CVD, incident diseases, and dietary intake.14 Diet
was assessed by trained dietitians who administered a 137-
item validated semiquantitative food frequency questionnaire
in a face-to-face interview.21,22 Energy and nutrient intakes
were computed using food composition tables.23-25 Partici-
pants also completed a 14-item dietary screener to assess
adherence to the MedDiet.26
Statistical Analysis
Rank-based inverse-normal transformations were used to
transform the markedly nonnormal distributions of our
primary exposures: circulating levels of Gln and Glu.27 We
also examined Gln:Glu as a metabolite trait (by dividing the
raw values and then taking inverse normal transformations)
because the ratio has been related to metabolic risk,2 and Gln
and Glu are in a precursor-product relationship.
Baseline data by case status were presented as means
(standard deviations) for continuous variables and as N and
percentages for categorical variables. Baseline characteristics
were compared between cases and noncases using chi-
squared tests for categorical variables and t tests for
continuous variables.
Our statistical approach sought to answer several ques-
tions: (1) Are baseline levels of these metabolites (Gln, Glu,
and their ratio) or their year-1 changes associated with the
risk of CVD clinical events? (2) Do the MedDiet interventions
change metabolite levels after 1 year? (3) Do metabolites
modify the effect of the MedDiet interventions on CVD risk?
To examine the ﬁrst question—the relationship of baseline
metabolites and ﬁrst-year changes in metabolite levels with
the risk of CVD events—we developed Cox proportional
hazards models adjusted for demographic and clinical char-
acteristics: in model 1, we adjusted for age (years), sex
(male/female), family history of CVD (yes/no), smoking
status (never, former, or current smoker), and body mass
index (BMI, kg/m2) and stratiﬁed by intervention group
(MedDiet+EVOO, MedDiet+nuts, and control diet); in model 2,
we further adjusted for baseline disease status, speciﬁcally
baseline hypertension, dyslipidemia, and diabetes mellitus
(yes/no for all). Because previous ﬁndings have suggested
that circulating BCAAs are highly related to cardiometabolic
risk,28 we considered an additional model that further
adjusted model 2 for total circulating BCAAs (as the sum of
untransformed levels of leucine, isoleucine, and valine,
followed by inverse normal transformation). There were
moderate correlations at baseline between plasma BCAAs
and Glu metabolites among subcohort members (Pearson
partial correlation coefﬁcients with adjustment for age, sex,
and BMI ranged from 0.32 to 0.36).
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The Glu metabolites were analyzed both as continuous
variables and in quartile categories (using cut-points deﬁned
from the quartile values among noncases). We conducted
tests of linear trend across increasing quartiles by using the
median value for each quartile and ﬁtting this as a continuous
variable in the models.
To assess the second question, we compared the mean
changes in metabolites from baseline to 1 year in the
MedDiet intervention groups with changes in the control
group. For the third question, we assessed whether baseline
levels of metabolites modiﬁed the cardioprotective effects of
MedDiets by introducing in the fully adjusted Cox models (as
described above) a multiplicative interaction term between
the baseline metabolite level (continuous) and the MedDiet
intervention groups (combined intervention groups vs
control).
In all Cox models, Barlow weights were used to account
for oversampling of cases in the study design.17 Noncases
in the subcohort were weighted inversely proportionally to
the sampling fraction (ie, in our study, the weight was 10).
For noncases, observation time began on the date of their
randomization and ended on their date of death (from
noncardiovascular causes), the study end date (December
1, 2010), or the date of the last medical visit (if they had
stopped attending scheduled intervention appointments),
whichever came ﬁrst. Cases had a weight of 1 at the
instant the individual experienced an endpoint regardless of
subcohort membership, and observation time was the
instant when the participant developed CVD. “Incident
internal cases” were treated as noncases (observation time
began on the date that they were randomized and ended
the instant the individual failed) until they became cases,
and at such instant their weight changed. We used a risk-
set approach and a robust variance estimator for the
multivariate modeling.29 We examined the possibly nonlin-
ear relation between metabolites and CVD risk nonpara-
metrically with restricted cubic splines in a multivariable
logistic regression model. Tests for nonlinearity used the
likelihood ratio test, comparing the model with only the
linear term to the model with the linear and the cubic
spline terms.
For the secondary outcome of incident stroke alone, we
conducted analyses both including and excluding the non-
stroke CVD cases (ie, keeping the 113 nonstroke CVD cases
and treating them as noncases or deleting them from
analyses) and found the results were similar. Therefore, we
present the stroke results only after deleting the nonstroke
CVD cases.
A P<0.05 was considered statistically signiﬁcant. All
statistical analyses were performed in SAS (v9.4, SAS
Institute, Cary, NC) and R (v2.13.0, R Foundation, Vienna,
Austria).
Results
Characteristics of the participants at baseline by quartiles of
Gln:Glu are shown in Table 1. The participants in our study
were, by design, middle-aged to elderly, generally over-
weight, and most had hypertension, dyslipidemia, or diabetes
mellitus at baseline. Participants who had a lower baseline
level of Gln:Glu were more likely to be male, diabetic, current
smokers, and they tended to weigh more, compared to
noncases.
Association of Baseline Metabolites and Changes
in Metabolites With Incident CVD
Table 2 shows the association of baseline levels of metabo-
lites with incident CVD. In the unadjusted model, baseline
levels of Glu were signiﬁcantly associated with increased risk;
that of Gln:Glu was associated with decreased CVD risk,
whether metabolites were modeled continuously (per 1 SD) or
as quartiles; Gln as a continuous variable was not associated
with CVD risk and as quartiles related to CVD risk. Adjustment
of baseline demographic factors (model 1) attenuated the
results somehow. After additional adjustment for baseline
disease status (model 2), per 1 SD, baseline Glu was
associated with 43% increased CVD risk (P=0.0008); partic-
ipants in the highest quartile of baseline Glu exhibited a
nonsigniﬁcantly increased risk of CVD compared to those in
the lowest quartile (HR Q4 vs Q1 [95% CI] 1.39 [0.84-2.31],
Ptrend=0.06). Per 1 SD, baseline Gln:Glu was signiﬁcantly
associated with 25% decreased risk of CVD (P=0.01);
participants in the highest quartile of the baseline Gln:Glu
ratio showed a nonsigniﬁcant 26% decreased risk of CVD
compared to those in the lowest quartile (HR Q4 vs Q1 [95%
CI] 0.74 [0.44-1.22], Ptrend=0.16). The associations of the
metabolites with the composite CVD endpoint appeared
nonlinear (model 2 in Table 2, P values for linear trend across
quartiles of Gln, Glu, and Gln:Glu=0.93, 0.06, and 0.16,
respectively). Spline analysis (Figure S2) suggested nonlinear
and signiﬁcant associations between these metabolites and
CVD risk (P value for nonlinearity with CVD risk of Gln was
0.002, of Glu was 0.001, and of Gln:Glu <0.001, and P value
for overall association of Gln was 0.003, of Glu <0.001, and of
Gln:Glu <0.001).
There was no evidence of interaction between sex and
the baseline metabolites on incident CVD (P values for
interaction >0.05). Additional adjustment of model 2 for
circulating BCAAs did not materially change the results
(Table S1).
Baseline levels of metabolites were more strongly and
linearly associated with the secondary stroke endpoint alone
than with the composite CVD endpoint (Table 3). In model 1,
baseline Glu levels were signiﬁcantly associated with
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increased stroke risk, and baseline levels of Gln and Gln:Glu
were signiﬁcantly associated with decreased stroke risk.
Further adjustment for disease status attenuated the asso-
ciation of Gln with stroke risk to nonsigniﬁcance, but the
associations of Glu and Gln:Glu with stroke risk remained. Per
1 SD, baseline Glu was associated with 81% increased risk of
stroke (P=1.49105); participants in the highest quartile of
baseline Glu had 3 times the risk of stroke of those in the
lowest quartile (HR Q4 vs Q1 [95% CI] 2.95 [1.44-6.03],
Ptrend=0.0008). Per 1-SD increment in baseline Gln:Glu, there
was a signiﬁcant 44% decreased risk of stroke (P=9.59105);
participants in the highest quartile of the Gln:Glu ratio had
less than half the risk of those in the lowest quartile (HR Q4 vs
Q1 [95% CI] 0.37 [0.18-0.76], Ptrend=0.005).
There were no statistically signiﬁcant associations of ﬁrst-
year changes in metabolites, adjusted for baseline levels, with
the risk of either composite CVD or stroke alone (Table S2).
Therefore, there was no basis to assess the hypothesis that
changes in these metabolites were potential mediators for the
effect of the intervention.
Effects of Dietary Interventions on Changes in
Metabolite Levels
There were no statistically signiﬁcant differences in mean
ﬁrst-year changes of metabolites between intervention and
control groups (Figure).
Modifying Effects of Metabolite Levels on Dietary
Interventions in Incident CVD
Effect modiﬁcation by baseline Glu of the combined MedDiet
interventions was statistically signiﬁcant in model 2 (P for
interaction=0.02) when we used the metabolites as contin-
uous variables in the interaction product term (1 df). This
suggests a greater protection against CVD by the MedDiet
among participants with higher baseline Glu levels than
among those with lower Glu levels. The combined MedDiet
interventions lowered CVD risk by 37% (HR [95% CI] 0.63
[0.40-0.99]) compared to the control diet among participants
with baseline Glu levels above the median; whereas the
interventions’ cardioprotective effects among participants
with baseline Glu levels below the median were not signiﬁcant
(HR [95% CI] 0.65 [0.37-1.12]). Figure S3 shows the joint
association of baseline Glu level and dietary intervention with
incident CVD risk. The common reference category in this
ﬁgure included participants in the control group with baseline
Glu levels above the median. The strongest reduction in risk
was observed for participants in both MedDiet groups
(merged together) with low baseline levels of Glu. The other
2 categories (control group and low Glu levels; MedDiet and
high Glu levels) presented an intermediate risk. Results were
consistent after further adjusting for 1-year changes in Glu
and when we limited the analyses to the secondary outcome
including only stroke cases. For the other 2 metabolite traits
(baseline Gln and the Gln:Glu ratio), there were no statistically
Table 1. Participant Characteristics at Baseline by Quartiles of Glutamine-to-Glutamate Ratio Among 980 Spanish Participants of
the PREDIMED Trial
Q1 (Low) Q2 Q3 Q4 (High)* P Value†
N 277 231 240 232
Age, y 67.036.2 67.556.0 68.346.0 67.516.1 0.16
Male, n (%) 148 (53.4) 113 (48.9) 110 (45.8) 81 (34.9) <0.001
BMI, kg/m2 30.673.6 29.773.5 29.593.5 28.743.7 <0.001
Hypertension, n (%) 228 (82.3) 187 (81.0) 202 (84.2) 200 (86.2) 0.45
Dyslipidemia, n (%) 186 (67.2) 169 (73.2) 174 (72.5) 163 (70.3) 0.43
Diabetes mellitus, n (%) 164 (59.2) 131 (56.7) 110 (45.8) 89 (38.4) <0.001
Family history of premature CHD, n (%) 64 (23.1) 57 (24.7) 56 (23.3) 60 (25.9) 0.88
Current smoker, n (%) 41 (14.8) 36 (15.6) 39 (16.3) 23 (9.9) 0.01
Intervention group
MedDiet+EVOO 106 (38.3) 79 (34.2) 80 (33.3) 98 (42.2) 0.32
MedDiet+nuts 88 (31.8) 77 (33.3) 87 (36.3) 62 (26.7)
Control 83 (30.0) 75 (32.5) 73 (30.4) 72 (31.0)
For continuous variables, meansstandard deviations are shown. For categorical variables, N and percentages are shown. BMI indicates body mass index; CHD, coronary heart disease;
CVD, cardiovascular disease; EVOO, extra-virgin olive oil; MedDiet, Mediterranean diet intervention group; PREDIMED, Prevencion con Dieta Mediterranea.
*Q1 to Q4: quartiles (using cut-points deﬁned from the quartile values among noncases).
†P value is derived from either linear regression or chi-squared test for the association of characteristics with quartile groups of metabolite.
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signiﬁcant interactions with the MedDiet interventions on risk
of CVD or stroke alone (P values for interaction=0.42 and
0.18 for CVD, respectively; 0.78 and 0.08 for stroke,
respectively).
Discussion
In this case-cohort study embedded in a randomized,
controlled dietary intervention trial, we found that Glu levels
were associated with higher risk and that Gln:Glu was
associated with lower risk of CVD. These associations were
more pronounced and linear when assessed against the risk
of stroke alone as opposed to all CVD events combined. Our
results suggest that participants with higher circulating
glutamate levels might especially beneﬁt from Mediterranean
diets. However, the intervention diets did not signiﬁcantly
change these metabolite levels.
The present research adds cardiovascular endpoints to the
evidence from prior smaller studies, which have primarily
investigated cardiometabolic risk factors.2 A recent study
investigated the metabolomic proﬁling in the Framingham
Heart Study (FHS) (n=1015) and replicated the ﬁndings in the
Table 2. Relative Risk of Incident Composite CVD by Baseline Glutamate-Related Metabolites: Hazard Ratios (95% CI) for
Metabolite Traits as Continuous Variables and by Quartile Levels of Metabolite Traits (N=980)
Glutamine Glutamate Glutamine-to-Glutamate Ratio
Unadjusted model
Metabolite as continuous variable
Hazard ratio (95% CI) per SD* 0.92 (0.76-1.10) 1.56 (1.30-1.86) 0.68 (0.57-0.83)
P value 0.36 <0.0001 0.0001
Metabolite in quartile categories,† as compared to Q1 (reference)
Q2 0.78 (0.52-1.19) 1.09 (0.68-1.74) 0.51 (0.34-0.77)
Q3 0.93 (0.62-1.40) 1.31 (0.83-2.06) 0.58 (0.39-0.86)
Q4 0.93 (0.62-1.39) 2.09 (1.36-3.23) 0.51 (0.34-0.78)
P for trend 0.04 0.0004 0.002
Model 1
Metabolite as continuous variable
Hazard ratio (95% CI) per SD* 0.90 (0.74-1.09) 1.48 (1.22-1.81) 0.71 (0.57-0.88)
P value 0.27 0.0001 0.002
Metabolite in quartile categories,† as compared to Q1 (reference)
Q2 0.64 (0.41-1.00) 0.83 (0.50-1.37) 0.51 (0.33-0.79)
Q3 0.85 (0.55-1.32) 1.04 (0.64-1.69) 0.55 (0.36-0.84)
Q4 0.85 (0.55-1.31) 1.60 (1.00-2.60) 0.64 (0.40-1.03)
P for trend 0.69 0.01 0.03
Model 2
Metabolite as continuous variable
Hazard ratio (95% CI) per SD* 0.94 (0.77-1.14) 1.43 (1.16-1.76) 0.75 (0.60-0.94)
P value 0.51 0.0008 0.01
Metabolite in quartile categories,† as compared to Q1 (reference)
Q2 0.74 (0.47-1.17) 0.78 (0.47-1.30) 0.56 (0.36-0.89)
Q3 1.03 (0.65-1.64) 0.97 (0.59-1.59) 0.65 (0.42-1.00)
Q4 0.94 (0.60-1.48) 1.39 (0.84-2.31) 0.74 (0.44-1.22)
P for trend 0.93 0.06 0.16
Q1 to Q4: quartiles. Model 1 was adjusted for age, sex, family history of CHD, smoking status, and body mass index and was stratiﬁed by intervention group. Model 2 was adjusted as for
model 1 plus baseline hypertension, dyslipidemia, and diabetes mellitus.
*The SD for glutamine was 202 lmol/L, and that for glutamate was 90 lmol/L in our study population.
†The corresponding medians of quartiles for glutamate were 71.8, 98.2, 114.6, and 150.2 lmol/L, respectively; for glutamine 656.7, 744.1, 795.0, and 891.3 lmol/L, respectively; and
for glutamine-to-glutamate ratio 4.9, 6.6, 8.3, 10.8, respectively.
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Malm€o Diet and Cancer Study (MDC) (n=746). The main
replicated ﬁndings included that circulating Glu levels were
positively related to awide range of cardiometabolic risk factors
including BMI, waist circumference, fasting glucose, insulin,
insulin resistance, and triglycerides and inversely related to
high-density lipoprotein cholesterol, whereas circulating levels
of Gln and the Gln:Glu exhibited opposite associations with
these cardiometabolic risk factors.2 In addition, in a subsample
of the Framingham Heart Study Offspring cohort, the Gln:Glu
ratio was associated with lower risk of incident type 2 diabetes
mellitus.2 Our population is comparable to those from the
abovementioned studies, even though both FHS and MDC
metabolomics studies were nested case-control studies
whereas ours is a case-cohort design. That our results were
more signiﬁcant for stroke as compared to CVD was not
unexpected; stroke is a more homogeneous endpoint than
composite CVD, and among the PREDIMED cases, stroke was
the single most common cardiovascular event.
These consistent associations between metabolites in the
Glu metabolism pathway further support the hypothesis that
Glu-cycling pathways are prominently involved in the devel-
opment of cardiometabolic risk and, in our study, in CVD and
especially stroke. Our results also add evidence for the
consideration of these metabolites as early markers of
Table 3. Relative Risk of Incident Stroke by Baseline Glutamate-Related Metabolites: Hazard Ratios (95% CI) for Metabolites as
Continuous Variables and by Quartile Levels of Metabolites (N=869)
Glutamine Glutamate Glutamine-to-Glutamate Ratio
Unadjusted model
Metabolite as continuous variable
Hazard ratio (95% CI) per SD* 0.76 (0.59-0.97) 1.80 (1.42-2.29) 0.56 (0.44-0.72)
P value 0.03 1.29106 6.29106
Metabolite in quartile categories,† as compared to Q1 (reference)
Q2 0.59 (0.34-1.02) 1.70 (0.85-3.39) 0.51 (0.30-0.86)
Q3 0.83 (0.50-1.37) 2.12 (1.09-4.15) 0.53 (0.32-0.88)
Q4 0.53 (0.30-0.94) 3.43 (1.81-6.50) 0.32 (0.18-0.59)
P for trend 0.06 <0.0001 0.0002
Model 1
Metabolite as continuous variable
Hazard ratio (95% CI) per SD* 0.73 (0.57-0.95) 1.87 (1.45-2.43) 0.53 (0.41-0.70)
P value 0.02 2.29106 7.69106
Metabolite in quartile categories,† as compared to Q1 (reference)
Q2 0.51 (0.28-0.91) 1.54 (0.76-3.13) 0.48 (0.27-0.84)
Q3 0.77 (0.46-1.31) 2.06 (1.04-4.09) 0.46 (0.27-0.79)
Q4 0.48 (0.26-0.86) 3.37 (1.69-6.72) 0.32 (0.16-0.63)
P for trend 0.04 0.0001 0.0005
Model 2
Metabolite as continuous variable
Hazard ratio (95% CI) per SD* 0.79 (0.62-1.01) 1.81 (1.39-2.37) 0.56 (0.42-0.75)
P value 0.06 1.49105 9.59105
Metabolite in quartile categories,† as compared to Q1 (reference)
Q2 0.60 (0.33-1.11) 1.40 (0.67-2.89) 0.51 (0.28-0.92)
Q3 0.97 (0.56-1.70) 1.92 (0.95-3.87) 0.54 (0.31-0.93)
Q4 0.55 (0.30-1.02) 2.95 (1.44-6.03) 0.37 (0.18-0.76)
P for trend 0.14 0.0008 0.005
Nonstroke cases were excluded. Q1 to Q4: quartiles. Model 1 was adjusted for age, sex, family history of CHD, smoking status, and body mass index and was stratiﬁed by intervention
group. Model 2 was adjusted as for model 1 plus baseline hypertension, dyslipidemia, and diabetes mellitus.
*The SD for glutamine was 202 lmol/L, and that for glutamate was 90 lmol/L in our study population.
†The corresponding medians of quartiles for glutamate were 71.8, 98.2, 114.6, and 150.2 lmol/L, respectively; for glutamine 656.7, 744.1, 795.0, and 891.3 lmol/L, respectively; and
for glutamine-to-glutamate ratio 4.9, 6.6, 8.3, 10.8, respectively.
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disease. Gln and Glu are transformed into each other as part
of numerous physiological processes. Cycling between Gln
and Glu is regulated by the activity of glutamine synthetase
and glutaminase, enzymes that have wide tissue distribu-
tion.30 The proposed mechanisms underlying the beneﬁcial
effects of Gln include a wide range of metabolic pathways,
such as stimulation of insulin secretion via enhancing release
of glucagon-like peptide 1 and improvement in insulin
sensitivity.9,31,32 Furthermore, Gln has a regulatory capacity
in immune cell modulation and has antiobesity and antidia-
betic effects.33 However, the potential mechanisms of the
adverse effects of Glu on cardiometabolic factors are less
clear. Both Glu and Gln are nonessential amino acids, and the
association of dietary intakes of these amino acids with CVD
risk is less studied.
To our knowledge, no study has previously reported on
changes in circulating Gln or Glu in relation to incident CVD.
Given that our study population already had high baseline risk
for CVD, the high and low levels of Glu and Gln, respectively,
likely already reﬂected an unfavorable metabolic state, which
may be 1 reason why changes in metabolite levels were not
signiﬁcantly associated with CVD risk when adjusted for the
baseline levels.
In addition to the repeated measurements of metabolites,
another important strength of our study is the assessment of
potential effect modiﬁcation by dietary intervention. Our
results suggest that participants with higher baseline Glu
levels might particularly beneﬁt from MedDiets in preventing
incident CVD compared to their lower-Glu counterparts. In
other words, the greater the dysfunction in Glu metabolism,
the more prominent the effects of changing the diet will be on
downstream disease events. This statistically signiﬁcant
effect modiﬁcation is important, and it may have a relevant
biological meaning. It is known that the type and amount of
fat in the diet not only modify blood lipid concentrations but
also change the cell membrane lipid composition. Therefore,
we suspect that the mechanism of such effect modiﬁcation
could be through changes in the composition and physical
properties of the cell membranes by the intervention with the
Mediterranean diets, which are dietary patterns high in total
fat and in unsaturated fat. This dietary intervention might have
led to alterations in the activities of membrane-bound
enzymes and carriers for glutamate metabolism.
Several limitations of the present study warrant mention.
First, our case-cohort study shares the limitations of the
original PREDIMED study, such as the limited generalizability
of the study’s conclusion. However, the present results can be
extended to all trial participants owing to the efﬁciency of the
case-cohort design; direct biomarker measurements of
the entire population would be cost-prohibitive. In addition,
the LC-MS-based metabolite measurements together with the
inverse-normal transformation may not have a direct clinical
translation for each metabolite trait. Third, we used a single
measure of metabolites at each of 2 time points, at baseline
and at year-1 visits. Using a single measurement relies on the
assumption that individual metabolite measurements are
consistent over a medium-term period, which may not hold in
reality. However, at least 1 previous study reported that both
circulating Glu and Gln were reproducible within individuals
over 1 to 2 years (intraclass correlations=0.6) using the same
LC-MS platform as in the present study.34
In summary, in this prospective study of older men and
women with high cardiovascular risk, our results suggest that
baseline levels of circulating Glu are related to increased
cardiovascular risk and that the ratio Gln:Glu is related to
decreased risk, especially with regard to stroke risk.
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Table S1. Relative risk of incident composite CVD by baseline glutamate-related metabolites: 
hazard ratios (95% CI) for metabolite traits as continuous variables and by quartile levels of 
metabolite traits (N=980) with adjustment for branch-chained amino acids. 
Glutamine Glutamate 
Glutamine-to-
Glutamate ratio 
Metabolite as continuous variable 
 Hazard Ratio (95%CI) per S.D.* 0.93 (0.77–1.14) 1.44 (1.17–1.79) 0.75 (0.60–0.94) 
 P 0.49 0.0008 0.01 
Metabolite in quartile categories,** as compared to Q1 (reference) 
 Q2 0.74 (0.47–1.17) 0.77 (0.46–1.30) 0.57 (0.36–0.90) 
 Q3 1.02 (0.65–1.63) 0.95 (0.56–1.59) 0.66 (0.43–1.03) 
 Q4 0.94 (0.60–1.48) 1.35 (0.80–2.29) 0.78 (0.46–1.31) 
 P for trend 0.95 0.10 0.23 
Q1 to Q4: quartiles. 
Model was adjusted for age, sex, family history of CHD, smoking status, body mass index plus 
baseline hypertension, dyslipidemia, and diabetes, and baseline levels of branch-chained amino 
acids, and was stratified by intervention group.  
* The S.D. for glutamine was 202 μmol/L, and for glutamate was 90 μmol/L in our study
population.  
** The corresponding medians of quartiles for glutamate were 71.8, 98.2, 114.6, and 150.2 
μmol/L, respectively; for glutamine 656.7, 744.1, 795.0 and 891.3 μmol/L, respectively; and for 
Glutamine-to-Glutamate ratio 4.9, 6.6, 8.3, 10.8, respectively. 
Table S2. Relationship between changes in metabolites from baseline to 1-year follow-up and 
the risk of composite CVD and stroke, The PREDIMED trial. 
*The changes in metabolites were the exposure variables. Models were adjusted for age, sex,
family history of CHD, smoking status, body mass index, baseline hypertension, dyslipidemia, 
diabetes, and respective baseline metabolite levels; stratified by intervention group. The analysis 
protocols were the same as that in Tables 2 and 3. 
Both baseline values and year-1 changes were inverse-normal transformed and treated as 
continuous variables. Tests of interaction between the baseline and year-1 values of the 
metabolites were not significant, and not retained in the models. The presented results were 
therefore based on models that excluded the multiplicative interaction term. All analyses 
excluded participants who developed CVD before the first year follow-up visit. 
Y1 change in 
Glutamine 
Y1 change in 
Glutamate 
Y1 change in Glutamine-
to-Glutamate ratio 
Incident CVD 
Hazard Ratio per S.D. 0.96 (0.74 – 1.24) 0.97 (0.78 – 1.21) 1.09 (0.86 – 1.38) 
P 0.72 0.80 0.49 
Incident stroke 
Hazard Ratio per S.D. 1.04 (0.75 – 1.42) 0.91 (0.71 – 1.17) 1.14 (0.85– 1.54) 
P 0.83 0.45 0.38 
Figure S1. Flowchart of the selection process of study participants. 
788 subcohort members 
N= 751 non-cases 
N=37“internal cases” 
7447 participants 
in PREDIMED 
794 subcohort* members 
(a random 10% of all) had 
plasma sample available 
(Including 37 cases, which 
were named “internal 
cases**”) 
231CVD cases (from 288 total 
cases) had plasma sample available 
(37 were from subcohort members, 
i.e., “internal cases”)
Baseline: 980 
N=751 non-cases 
N=229 CVD cases 
(980=788+229-37overlapped cases) 
1-year visit: 923 
N=747 non-cases 
N=176 CVD cases 
Exclusions 
n=3 had missing metabolite 
values at baseline 
n=5 had metabolite outliers 
identified by quality control 
229 CVD cases 
(37 were “internal cases”) 
*subcohort: a random, non-stratified sample of approximately 10% of PREDIMED participants at
baseline. 
** incident cases which were subcohort members. 
Figure S2. Spline of levels of glutamate-related metabolites and incident CVD. Dotted lines 
are 95% confidence intervals of the spline; horizon line is the reference. We used logistic 
regression to analyze the spline analysis of the association between metabolites and CVD, 
because results from logistic regression approximate those from Cox proportional hazards 
regression in general,
1, 2 
and the use of a Cox model for spline analysis in the setting of a case-
cohort design is not well established. 
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Figure S3. Hazard Ratios of cardiovascular risk by baseline high vs. low glutamate levels and 
intervention vs. control groups.  
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